“Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab for 52 Weeks”, J of Skin, vol. 8, no. 2, p. s377, Mar. 2024, doi: 10.25251/skin.8.supp.377.